Yahoo Finance

Tessellate BIO, an Emerging Precision Oncology Company, Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board

AMSTERDAM and LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment ...
Yahoo Finance

Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer

NAARDEN, the Netherlands and STEVENAGE, United Kingdom, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, ...
FierceBiotech

Boehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($570 ...
Hosted on MSN

Boehringer to expand oncology presence with $572m Tessellate Bio deal

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...
Pharmabiz

Tessellate BIO, Omico & CMRI collaborate to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian paediatric medical research ...
manilatimes

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer

AMSTERDAM and STEVENAGE, United Kingdom, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today ...